The purpose of the CAMONA study is to demonstrate the feasibility of cardiovascular molecular calcification (CMC) assessment by means of 18F-sodium-fluoride (18F-NaF) positron emission tomography (PET) computed tomography (CT) in a prospective cohort of healthy control subjects and subjects with cardiovascular disease.
Atherosclerosis associated cardiovascular disease (CVD) remains a significant cause of morbidity and mortality. Asymptomatic individuals with a moderate to high-risk of developing acute atherosclerotic cardiovascular events will benefit most from intensive evidence-based medical interventions. The traditional approach to identify patients with moderate to high-risk of CVD involves quantifying the presence of CVD risk factors. Based on gender, age, smoking, systolic blood pressure and cholesterol levels, risk stratification algorithms such as the Framingham Risk Score (FRS) and the European SCORE system can predict the 10-year risk of cardiovascular death. However, these algorithms are associated with several limitations, including misclassification of women and individuals with high levels of a single risk factor. The risk is underestimated in these individuals. Therefore, these individuals are not eligible for treatment by current criteria of CVD prevention guidelines. Several studies indicate that the traditional risk score models leave room for improvement, as they work reasonably well for populations, but remain suboptimal for individual subjects. New risk parameters are discovered on a regular basis. One of these parameters is cardiovascular molecular calcification (CMC). This entity can be detected and quantified by 18F-NaF PET CT. It has been hypothesized that CMC can be detected years, maybe even decades, before coronary artery calcium scoring (CACS) can be detected by conventional imaging modalities like multislice CT. Theoretically, this tool can detect patients at a very early stage of the disease. Providing evidence-based treatment to these individuals can, theoretically, improve the prevention of CVD. Before this hypothesises can be tested, the feasibility of 18F-NaF PET CT has to be demonstrated in both healthy controls as well as in subjects with cardiovascular disease.
Study Type
OBSERVATIONAL
Enrollment
144
Department of Cardiology, Odense University Hospital
Odense, Region Syddanmark, Denmark
RECRUITINGDepartment of Nuclear Medicine, Odense University Hospital
Odense, Region Syddanmark, Denmark
RECRUITINGStandardized uptake value (SUV) of 18F-NaF
The SUV is a validated semi-quantitative assessment of PET radiotracer uptake. The SUV of 18F-NaF will be determined in the aorta, carotid arteries, coronary arteries, iliac arteries and the femoral arteries.
Time frame: Up to 7 days after the day of PET CT acquisition
Target to background ratio (TBR) of 18F-NaF
The TBR is a validated semi-quantitative assessment of PET radiotracer uptake. The TBR of 18F-NaF will be determined in the aorta, carotid arteries, coronary arteries, iliac arteries and the femoral arteries.
Time frame: Up to 7 days after the day of PET CT acquisition
Standardized uptake value (SUV) of 18F-Fluorodeoxyglucose (18F-FDG)
The SUV is a validated semi-quantitative assessment of PET radiotracer uptake. The SUV of 18F-FDG will be determined in the aorta, carotid arteries, iliac arteries and the femoral arteries.
Time frame: Up to 7 days after the day of PET CT acquisition
Target to background ratio (TBR) of 18F-FDG
The TBR is a validated semi-quantitative assessment of PET radiotracer uptake. The TBR of 18F-FDG will be determined in the aorta, carotid arteries, iliac arteries and the femoral arteries.
Time frame: Up to 7 days after the day of PET CT acquisition
Correlation between the TBR of 18F-NaF/18F-FDG and traditional cardiovascular risk factors.
The traditional cardiovascular risk factors consist of: 1. Smoking, pack years; 2. Alcohol, units/week; 3. Blood pressure, mean arterial pressure, mmHg; 4. Body mass index, kg/m2; 5. Waist circumference, cm; 6. History of cardiovascular disease; 7. Family history of cardiovascular disease; 8. Medication usage; 9. Age; 10. Gender.
Time frame: The cardiovascular risk factors will be determined, on average, 1 hour before 18F-NaF / 18F-FDG injection; which ever comes first
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Correlation between the TBR of 18F-NaF/18F-FDG and blood markers of atherosclerosis.
Blood markers: 1. Total cholesterol, mmol/L; 2. LDL cholesterol, mmol/L; 3. HDL cholesterol, mmol/L; 4. Triglycerides, mmol/L; 5. Homocysteine, mmol/L; 6. Fasting plasma glucose, mmol/L; 7. HBA1c, mmol/mol; 8. High sensitivity C-reactive protein, nmol/L; 9. Fibrinogen, umol/L; 10. Leukocyte differentiation, cells/L; 11. Creatinine, umol/L;
Time frame: The blood draw will be performed, on average, 1 hour before the 18F-FDG PET CT scan and the blood markers will determined in upto 48 hours after the 18F-FDG PET CT scan
Correlations between 18F-NaF TBR, 18F-FDG TBR, and CT calcification scoring
Correlation between the degree of 18F-NaF uptake, 18F-FDG uptake, CT-Calcification scoring and the various arterial segments (aorta, carotid arteries, iliac arteries and the femoral arteries.
Time frame: Up to 7 days after the day of PET CT acquisition
Target to background ratio (TBR) of 18F-NaF
18F-NaF PET/CT images will be acquired at 45, 90 and 180 minutes after intravenous injection of the compound in a subset of 40 patients. The TBR of 18F-NaF will be determined at each time point and compared to allow determining the optimum tracer circulation time for maximum contrast between the vessel wall and blood pool.
Time frame: Up to 7 days after the day of PET CT acquisition
Target to background ratio (TBR) of 18F-FDG
18F-FDG PET/CT images will be acquired at 90 and 180 minutes after intravenous injection of the compound in a subset of 40 patients. The TBR of 18F-NaF will be determined at both time points and compared to allow determining the optimum tracer circulation time for maximum contrast between the vessel wall and blood pool.
Time frame: Up to 7 days after the day of PET CT acquisition
Correlation between 18F-NaF / 18F-FDG uptake and 18F-FDG uptake in the brain
18F-FDG uptake in the brain will be quantified by calculating the mean and maximum partial-volume corrected SUV.
Time frame: Up to 7 days after the day of PET CT acquisition
Correlation between 18F-NaF TBR and 18F-NaF TBR two years after the baseline scan.
The TBR will be determined in various segments of the arterial tree.
Time frame: 2 years
Correlation between 18F-FDG TBR and 18F-FDG TBR two years after the baseline scan.
The TBR will be determined in various segments of the arterial tree.
Time frame: 2 years
Correlation between the TBR of 18F-NaF/18F-FDG and HeartSCORE
The HeartSCORE will be calculated according to the current HeartSCORE protocol for Denmark.
Time frame: Up to 7 days after the day of PET CT acquisition
Correlation between the TBR of 18F-NaF/18F-FDG and Framingham Risk Score
The Framingham Risk Score will be calculated according to the current recommendations by the Framingham Heart Study group
Time frame: Up to 7 days after the day of PET CT acquisition
Correlation between 18F-NaF / 18F-FDG uptake and 18F-NaF / 18F-FDG uptake in the vertebral body
18F-NaF uptake in the 1st, 3rd and 5th lumbar vertebral body will be quantified by calculating the mean and maximum partial-volume corrected SUV.
Time frame: Up to 7 days after the day of PET CT acquisition
Arterial Calcification Score
Arterial Calcification Scoring will be determined in Agatston Units as well as in volumetric units in all segments of the arterial tree (coronary arteries, aorta, carotid arteries, iliac and femoral arteries.
Time frame: Up to 7 days after the day of PET CT acquisition